Rare coding variants in ten genes confer substantial risk for schizophrenia

doi:10.1038/s41586-022-04556-w

. 2022 Apr;604(7906):509-516.

doi: 10.1038/s41586-022-04556-w. Epub 2022 Apr 8.

Rare coding variants in ten genes confer substantial risk for schizophrenia

Tarjinder Singh^{1

2

3}, Timothy Poterba^{4

5}, David Curtis^{6

7}, Huda Akil⁸, Mariam Al Eissa⁹, Jack D Barchas¹⁰, Nicholas Bass⁹, Tim B Bigdeli¹¹, Gerome Breen¹², Evelyn J Bromet¹³, Peter F Buckley¹⁴, William E Bunney¹⁵, Jonas Bybjerg-Grauholm^{16

17}, William F Byerley¹⁸, Sinéad B Chapman⁵, Wei J Chen¹⁹, Claire Churchhouse^{4

5}, Nicholas Craddock²⁰, Caroline M Cusick⁵, Lynn DeLisi²¹, Sheila Dodge²², Michael A Escamilla²³, Saana Eskelinen^{24

25}, Ayman H Fanous²⁶, Stephen V Faraone²⁷, Alessia Fiorentino⁹, Laurent Francioli^{4

28}, Stacey B Gabriel²², Diane Gage⁵, Sarah A Gagliano Taliun^{29

30}, Andrea Ganna^{4

31}, Giulio Genovese⁵, David C Glahn³², Jakob Grove^{16

33

34

35}, Mei-Hua Hall³⁶, Eija Hämäläinen³¹, Henrike O Heyne^{4

5

31}, Matti Holi³⁷, David M Hougaard^{16

17}, Daniel P Howrigan^{4

5}, Hailiang Huang^{4

5}, Hai-Gwo Hwu³⁸, René S Kahn^{39

40}, Hyun Min Kang⁴¹, Konrad J Karczewski^{4

5}, George Kirov⁴², James A Knowles⁴³, Francis S Lee¹⁰, Douglas S Lehrer⁴⁴, Francesco Lescai^{16

45}, Dolores Malaspina³⁹, Stephen R Marder³⁹, Steven A McCarroll^{5

46}, Andrew M McIntosh⁴⁷, Helena Medeiros²⁶, Lili Milani⁴⁸, Christopher P Morley^{27

49}, Derek W Morris⁵⁰, Preben Bo Mortensen⁵¹, Richard M Myers⁵², Merete Nordentoft^{16

53

54}, Niamh L O'Brien⁹, Ana Maria Olivares⁵, Dost Ongur³⁶, Willem H Ouwehand⁵⁵, Duncan S Palmer^{4

5}, Tiina Paunio⁵⁶, Digby Quested⁵⁷, Mark H Rapaport⁵⁸, Elliott Rees⁴², Brandi Rollins¹⁵, F Kyle Satterstrom^{4

5

59}, Alan Schatzberg⁶⁰, Edward Scolnick⁵, Laura J Scott⁴¹, Sally I Sharp⁹, Pamela Sklar³⁹, Jordan W Smoller^{60

61}, Janet L Sobell⁶², Matthew Solomonson²⁸, Eli A Stahl³⁹, Christine R Stevens^{5

28}, Jaana Suvisaari⁶³, Grace Tiao²⁸, Stanley J Watson⁸, Nicholas A Watts²⁸, Douglas H Blackwood⁶⁴, Anders D Børglum^{16

33

34}, Bruce M Cohen³⁶, Aiden P Corvin⁶⁵, Tõnu Esko⁴⁸, Nelson B Freimer⁶⁶, Stephen J Glatt²⁷, Christina M Hultman⁶⁷, Andrew McQuillin⁹, Aarno Palotie^{4

5

28

31

60}, Carlos N Pato¹¹, Michele T Pato¹¹, Ann E Pulver⁶⁷, David St Clair⁶⁸, Ming T Tsuang⁶⁹, Marquis P Vawter¹⁵, James T Walters⁴², Thomas M Werge^{16

54

70

71}, Roel A Ophoff^{72

73}, Patrick F Sullivan^{74

75}, Michael J Owen⁴², Michael Boehnke⁴¹, Michael C O'Donovan⁴², Benjamin M Neale^#^{76

77

78}, Mark J Daly^#^{79

80

81

82}

Affiliations

¹ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. tsingh@broadinstitute.org.
² Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. tsingh@broadinstitute.org.
³ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. tsingh@broadinstitute.org.
⁴ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
⁵ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
⁶ UCL Genetics Institute, University College London, London, UK.
⁷ Centre for Psychiatry, Queen Mary University London, London, UK.
⁸ Department of Psychiatry, Michigan Neuroscience Institute, Medical School, University of Michigan, Ann Arbor, MI, USA.
⁹ Division of Psychiatry, University College London, London, UK.
¹⁰ Weill Cornell Medical College, New York, NY, USA.
¹¹ Department of Psychiatry and Behavioral Sciences, SUNY Downstate College of Medicine, Brooklyn, NY, USA.
¹² Social Genetic and Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
¹³ Department of Psychiatry and Behavioral Health, Health Sciences Center, Stony Brook University, Stony Brook, NY, USA.
¹⁴ Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA.
¹⁵ Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA.
¹⁶ Lundbeck Foundation Initiative for Integrative Psychiatric Research, Copenhagen, Denmark.
¹⁷ Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.
¹⁸ Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA.
¹⁹ College of Public Health, National Taiwan University, Taipei, Taiwan.
²⁰ National Centre for Mental Health, Cardiff University, Cardiff, UK.
²¹ Department of Psychiatry, Cambridge Health Alliance, Cambridge Hospital, Cambridge, MA, USA.
²² Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
²³ Texas Tech University Health Sciences Center, El Paso, TX, USA.
²⁴ University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
²⁵ Department of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
²⁶ Department of Psychiatry and Behavioral Sciences, SUNY Downstate Medical Center, Brooklyn, NY, USA.
²⁷ Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA.
²⁸ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
²⁹ Faculté de Médecine, Université de Montréal, Montreal, Quebec, Canada.
³⁰ Montréal Heart Institute, Montreal, Quebec, Canada.
³¹ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
³² Department of Psychiatry, Boston Children's Hospital, Boston, MA, USA.
³³ Department of Biomedicine and Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark.
³⁴ Center for Genomics and Personalized Medicine, Aarhus, Denmark.
³⁵ Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.
³⁶ McLean Hospital, Harvard Medical School, Belmont, MA, USA.
³⁷ Department of Psychiatry, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
³⁸ Department of Psychiatry, National Taiwan University, Taipei, Taiwan.
³⁹ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴⁰ MIRECC, JP Peters VA Hospital, Bronx, NY, USA.
⁴¹ Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA.
⁴² MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
⁴³ Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
⁴⁴ Department of Psychiatry, Wright State University, Dayton, OH, USA.
⁴⁵ Department of Biomedicine, Aarhus University, Aarhus, Denmark.
⁴⁶ Department of Genetics, Harvard Medical School, Boston, MA, USA.
⁴⁷ University of Edinburgh, Edinburgh, UK.
⁴⁸ Institute of Genomics, University of Tartu, Tartu, Estonia.
⁴⁹ Department of Public Health and Preventive Medicine and Department of Family Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
⁵⁰ National University of Ireland, Galway, Ireland.
⁵¹ Aarhus University, Aarhus, Denmark.
⁵² HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
⁵³ Copenhagen Research Center for Mental Health, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark.
⁵⁴ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
⁵⁵ University of Cambridge, Cambridge, UK.
⁵⁶ Department of Psychiatry, University of Helsinki, Helsinki, Finland.
⁵⁷ Oxford Health NHS Foundation Trust, Oxford, UK.
⁵⁸ Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA.
⁵⁹ Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
⁶⁰ Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
⁶¹ Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
⁶² Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
⁶³ Finnish Institute for Health and Welfare, Helsinki, Finland.
⁶⁴ Department of Psychiatry, University of Edinburgh, Edinburgh, UK.
⁶⁵ Trinity College Dublin, Dublin, Ireland.
⁶⁶ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
⁶⁷ School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
⁶⁸ University of Aberdeen, Aberdeen, UK.
⁶⁹ Center for Behavioral Genomics, Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
⁷⁰ Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark.
⁷¹ Center for GeoGenetics, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark.
⁷² Center for Neurobehavioral Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
⁷³ Department of Psychiatry, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
⁷⁴ Karolinska Institute, Solna, Sweden.
⁷⁵ University of North Carolina, Chapel Hill, NC, USA.
⁷⁶ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. bneale@broadinstitute.org.
⁷⁷ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. bneale@broadinstitute.org.
⁷⁸ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. bneale@broadinstitute.org.
⁷⁹ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. mjdaly@atgu.mgh.harvard.edu.
⁸⁰ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. mjdaly@atgu.mgh.harvard.edu.
⁸¹ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. mjdaly@atgu.mgh.harvard.edu.
⁸² Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. mjdaly@atgu.mgh.harvard.edu.

^# Contributed equally.

PMID: 35396579
PMCID: PMC9805802
DOI: 10.1038/s41586-022-04556-w

Rare coding variants in ten genes confer substantial risk for schizophrenia

Tarjinder Singh et al. Nature. 2022 Apr.

. 2022 Apr;604(7906):509-516.

doi: 10.1038/s41586-022-04556-w. Epub 2022 Apr 8.

Authors

Affiliations

¹ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. tsingh@broadinstitute.org.
² Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. tsingh@broadinstitute.org.
³ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. tsingh@broadinstitute.org.
⁴ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
⁵ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
⁶ UCL Genetics Institute, University College London, London, UK.
⁷ Centre for Psychiatry, Queen Mary University London, London, UK.
⁸ Department of Psychiatry, Michigan Neuroscience Institute, Medical School, University of Michigan, Ann Arbor, MI, USA.
⁹ Division of Psychiatry, University College London, London, UK.
¹⁰ Weill Cornell Medical College, New York, NY, USA.
¹¹ Department of Psychiatry and Behavioral Sciences, SUNY Downstate College of Medicine, Brooklyn, NY, USA.
¹² Social Genetic and Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
¹³ Department of Psychiatry and Behavioral Health, Health Sciences Center, Stony Brook University, Stony Brook, NY, USA.
¹⁴ Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA.
¹⁵ Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA, USA.
¹⁶ Lundbeck Foundation Initiative for Integrative Psychiatric Research, Copenhagen, Denmark.
¹⁷ Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.
¹⁸ Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA.
¹⁹ College of Public Health, National Taiwan University, Taipei, Taiwan.
²⁰ National Centre for Mental Health, Cardiff University, Cardiff, UK.
²¹ Department of Psychiatry, Cambridge Health Alliance, Cambridge Hospital, Cambridge, MA, USA.
²² Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
²³ Texas Tech University Health Sciences Center, El Paso, TX, USA.
²⁴ University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
²⁵ Department of Public Health Solutions, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
²⁶ Department of Psychiatry and Behavioral Sciences, SUNY Downstate Medical Center, Brooklyn, NY, USA.
²⁷ Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA.
²⁸ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
²⁹ Faculté de Médecine, Université de Montréal, Montreal, Quebec, Canada.
³⁰ Montréal Heart Institute, Montreal, Quebec, Canada.
³¹ Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
³² Department of Psychiatry, Boston Children's Hospital, Boston, MA, USA.
³³ Department of Biomedicine and Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark.
³⁴ Center for Genomics and Personalized Medicine, Aarhus, Denmark.
³⁵ Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.
³⁶ McLean Hospital, Harvard Medical School, Belmont, MA, USA.
³⁷ Department of Psychiatry, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
³⁸ Department of Psychiatry, National Taiwan University, Taipei, Taiwan.
³⁹ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴⁰ MIRECC, JP Peters VA Hospital, Bronx, NY, USA.
⁴¹ Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA.
⁴² MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
⁴³ Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
⁴⁴ Department of Psychiatry, Wright State University, Dayton, OH, USA.
⁴⁵ Department of Biomedicine, Aarhus University, Aarhus, Denmark.
⁴⁶ Department of Genetics, Harvard Medical School, Boston, MA, USA.
⁴⁷ University of Edinburgh, Edinburgh, UK.
⁴⁸ Institute of Genomics, University of Tartu, Tartu, Estonia.
⁴⁹ Department of Public Health and Preventive Medicine and Department of Family Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
⁵⁰ National University of Ireland, Galway, Ireland.
⁵¹ Aarhus University, Aarhus, Denmark.
⁵² HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
⁵³ Copenhagen Research Center for Mental Health, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark.
⁵⁴ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
⁵⁵ University of Cambridge, Cambridge, UK.
⁵⁶ Department of Psychiatry, University of Helsinki, Helsinki, Finland.
⁵⁷ Oxford Health NHS Foundation Trust, Oxford, UK.
⁵⁸ Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA.
⁵⁹ Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
⁶⁰ Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
⁶¹ Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
⁶² Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
⁶³ Finnish Institute for Health and Welfare, Helsinki, Finland.
⁶⁴ Department of Psychiatry, University of Edinburgh, Edinburgh, UK.
⁶⁵ Trinity College Dublin, Dublin, Ireland.
⁶⁶ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
⁶⁷ School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
⁶⁸ University of Aberdeen, Aberdeen, UK.
⁶⁹ Center for Behavioral Genomics, Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
⁷⁰ Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark.
⁷¹ Center for GeoGenetics, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark.
⁷² Center for Neurobehavioral Genetics, University of California, Los Angeles, Los Angeles, CA, USA.
⁷³ Department of Psychiatry, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
⁷⁴ Karolinska Institute, Solna, Sweden.
⁷⁵ University of North Carolina, Chapel Hill, NC, USA.
⁷⁶ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. bneale@broadinstitute.org.
⁷⁷ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. bneale@broadinstitute.org.
⁷⁸ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. bneale@broadinstitute.org.
⁷⁹ Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. mjdaly@atgu.mgh.harvard.edu.
⁸⁰ Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. mjdaly@atgu.mgh.harvard.edu.
⁸¹ Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. mjdaly@atgu.mgh.harvard.edu.
⁸² Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. mjdaly@atgu.mgh.harvard.edu.

^# Contributed equally.

PMID: 35396579
PMCID: PMC9805802
DOI: 10.1038/s41586-022-04556-w

Abstract

Rare coding variation has historically provided the most direct connections between gene function and disease pathogenesis. By meta-analysing the whole exomes of 24,248 schizophrenia cases and 97,322 controls, we implicate ultra-rare coding variants (URVs) in 10 genes as conferring substantial risk for schizophrenia (odds ratios of 3-50, P < 2.14 × 10^-6) and 32 genes at a false discovery rate of <5%. These genes have the greatest expression in central nervous system neurons and have diverse molecular functions that include the formation, structure and function of the synapse. The associations of the NMDA (N-methyl-D-aspartate) receptor subunit GRIN2A and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor subunit GRIA3 provide support for dysfunction of the glutamatergic system as a mechanistic hypothesis in the pathogenesis of schizophrenia. We observe an overlap of rare variant risk among schizophrenia, autism spectrum disorders¹, epilepsy and severe neurodevelopmental disorders², although different mutation types are implicated in some shared genes. Most genes described here, however, are not implicated in neurodevelopment. We demonstrate that genes prioritized from common variant analyses of schizophrenia are enriched in rare variant risk³, suggesting that common and rare genetic risk factors converge at least partially on the same underlying pathogenic biological processes. Even after excluding significantly associated genes, schizophrenia cases still carry a substantial excess of URVs, which indicates that more risk genes await discovery using this approach.

PubMed Disclaimer

Conflict of interest statement

Competing Interests

M.J.D. is a founder of Maze Therapeutics and RBNC Therapeutics. B.M.N. is a member of the scientific advisory board at Deep Genomics and RBNC Therapeutics, Member of the scientific advisory committee at Milken and a consultant for Camp4 Therapeutics, Merck and Biogen. A.P. is a member of Astra Zeneca’s Genomics Advisory Board. M.C.O, M.J.O, and J.T.W. are supported by a collaborative research grant from Takeda Pharmaceuticals. D.S.P. was an employee of Genomics plc, all analyses reported in this paper were performed as part of D.S.P.’s employment at the Massachusetts General Hospital and Broad Institute. The remaining authors declare no competing interests.

Figures

**Extended Data Figure 1.. Schizophrenia case-control enrichment in constrained genes (pLI > 0.9) in different SCHEMA cohorts (n = 22,444 cases and n = 39,837 controls).**
The odds ratio and standard error of PTVs and Synonymous variants are provided for each cohort. The meta-analyzed odds ratio and standard error is calculated using inverse-variance. PTVs show consistent signals across the different cohorts, and synonymous variants do not deviate from expectation. Bars represent the 95% CIs of the point estimates.

Extended Data Figure 2.. Schizophrenia case-control enrichment in constrained genes (pLI > 0.9) stratified by different variant annotations and inferred consequences (n = 22,444 cases and n = 39,837 controls).
LoF: all loss-of-function or PTVs; LoFHC: high-confidence LOFTEE PTVs; LoFLC: low-confidence based on LOFTEE; MPC > 3: missense variants with MPC > 3; MPC 2 – 3: missense variants with MPC 2 – 3; Other missense: missense variants with MPC < 2; Syn: synonymous variants. The dot represents the odds ratio, and the bars represent the 95% CIs of the point estimates.

**Extended Data Figure 3.. Enrichment of URVs in n = 4,403 ASD and n = 3,292 ADHD cases compared to n = 5,220 controls stratified by variant annotation and consequences in constrained genes (pLI > 0.9).**
Two-sided P values from logistic regression displayed are from comparing the burden of variants of the labeled consequence in cases compared to controls. The dot represents the odds ratio, and the bars represent the 95% CIs of the point estimates.

**Extended Data Figure 4.. Schizophrenia case-control gene set enrichment in brain and non-brain GTEx tissues.**
We test for the burden of rare PTVs in genes with the strongest specific expression in that tissue type relative to other tissues as defined in . Gene set burden statistics are calculated using a logistic regression model of rare variants from n = 22,444 cases and n = 39,837 controls. We report two-sided P values. Each bar is a different tissue in GTEx, grouped by whether it is part of the central nervous system and sorted by P value (Table S8).

**Figure 1.. Study design and analytic approach.**
A: Study design. Case-control and parent-proband trio sample sizes, variant classes, and analytical methods are described. The case-control stage is shown on the left, and the *de novo* mutation stage is shown on the right. B: Principal components analysis of SCHEMA samples. 1000 Genomes samples with reported ancestry are plotted in the background, and SCHEMA samples are displayed in the foreground. For each global ancestry group, we report the number of cases and controls in the discovery data set in red and blue respectively, and the number of external controls in black. AFR: African, ASJ: Ashkenazi Jewish, AMR: Latin American, EAS: East Asian, EST: Estonian, FIN: Finnish, EUR: non-Finnish European, SAS: South Asian. C: Case-control enrichment of ultra-rare protein-coding variants in genes intolerant of protein-truncating variants (n = 22,444 cases and n = 39,837 controls). Two-sided P values from logistic regression displayed are from comparing the burden of variants of the labeled consequence in cases compared to controls. By definition, MPC enrichment is only shown for pLI > 0.9 genes. The dot represents the odds ratio, and the bars represent the 95% CIs of the point estimates. pLI: probability of loss-of-function intolerant in the gnomAD database. D: Enrichment of schizophrenia *de novo* mutations in P value bins derived from the Stage 1 (case-control) gene burden analysis (n = 3,402 schizophrenia trios). The one-sided enrichment P values displayed are calculated as a Poisson probability having equal or greater than the observed number of mutations given the baseline mutation rate. The relative rate is given by the ratio of observed to expected rate of *de novo* mutations. The dot represents the relative rate, and the bars represent the 95% CIs of the point estimates.

**Figure 2.. Results from the meta-analysis of ultra-rare coding variants in 3,402 trios, 24,248 cases, and 97,322 controls.**
A: Manhattan plot. −log₁₀ P values are plotted against the chromosomal location of each gene. The per-gene P values are calculated by meta-analyzing two-sided burden test P values from rare coding variants in 24,248 cases and 97,322 controls, and one-sided Poisson rate test P values from *de novo* mutations in 3,402 trios (see text and Supplementary Methods for more information). Genes reaching exome-wide significance (P < 2.14 × 10⁻⁶ corresponding to 0.05/23,321 tests) are in red, and genes significant at FDR < 5% are in orange. Red dashed line: P = 2.14 × 10⁻⁶; Blue dashed line: FDR < 5%, or *P =* 8.23 × 10^-5. B: Q-Q plot. Observed −log₁₀ P values are plotted against expectation given a uniform distribution. The per-gene P values are calculated by meta-analyzing two-sided burden test P values from rare coding variants in 24,248 cases and 97,322 controls, and one-sided Poisson rate test P values from *de novo* mutations in 3,402 trios (see text and Supplementary Methods for more information). Genes reaching exome-wide significance are plotted with a larger size. The direction of effect is indicated by the color of each point. The gray shaded area indicates the 95% CI under the null. Dark blue dashed line: P = 2.14 × 10⁻⁶; Light blue dashed line: FDR < 5%.

**Figure 3.. Biological insights from exome sequence data.**
A: Common and rare allelic series at NMDA receptor subunit *GRIN2A*. The Locus Zoom plot (top) displays the common variant (GWAS) association of the gene. The two-sided P values of each SNP from the GWAS meta-analysis are shown along the y-axis. The color of each dot corresponds to the LD with the index SNP, and the properties of the index SNP are displayed. The gene plot (bottom) displays the protein-coding variants that contribute to the exome signal in *GRIN2A*. Variants discovered in cases are plotted above the gene, and those from control are plotted below. Each variant is colored based on inferred consequence, and the protein domains and missense constrained regions of the gene are also labelled^,. The frequencies and counts in cases and controls are displayed for each variant class. AF: allele frequency, AC: allele count. B: Temporal expression of *GRIN2A* in the human brain (n = 42 samples). We show *GRIN2A* expression in four prenatal and four postnatal periods derived from whole-brain tissue in BrainSpan. The expression values plotted are in transcript-per-million (TPM). In the box plot, the lower hinge is the 25% quantile, the middle line is the median, the upper hinge is the 75% quantile, the lower whisker extends to the smallest observation greater than or equal to the lower hinge − 1.5 * IQR, and the upper whisker extends to the largest observation less than or equal to the upper hinge + 1.5 * IQR.

**Figure 4.. Shared genetic signal with schizophrenia GWAS.**
A: Case-control enrichment of ultra-rare protein-coding variants in genes prioritized from fine-mapping of the PGC schizophrenia GWAS (n = 22,444 cases and n = 39,837 controls). The reported P value is from applying the Fisher’s combined probability method on the two-sided P values of Class I and Class II variants. The dot represents the odds ratio, and the bars represent the 95% CIs of the point estimates. **B, C, D:** Prioritization of GWAS loci using exome data. The Locus Zoom plot of three GWAS loci is displayed. The two-sided P values of each SNP from the GWAS meta-analysis are shown along the y-axis. Below, for each gene in or adjacent to the region, we show the case-control counts of PTVs in the exome data, along with the two-sided burden test meta-analysis P values. *SP4, STAG1* and *FAM120A* are highlighted as the only genes with notable signals in the exome data within each locus.

**Figure 5.. Shared genetic signal between schizophrenia and other neurodevelopmental disorders.**
A: Case-control enrichment of ultra-rare protein-coding variants in DD/ID and ASD-associated genes (n = 22,444 cases and n = 39,837 controls). We test for the burden of schizophrenia URVs in genes identified in the most recent exome sequencing studies of ASD and DD/ID^,. The reported P value is from applying the Fisher’s combined probability method on the two-sided P values of Class I and Class II variants. The dot represents the odds ratio, and the bars represent the 95% CIs of the point estimates. B: Heatmap displaying the strength of association for schizophrenia-associated genes in our discovery data set and in genes implicated by *de novo* mutations in trios diagnosed with DD/ID. We display three groups of genes: Bonferroni significant in schizophrenia and DD/ID, Bonferroni significant only in schizophrenia, and FDR < 5% in schizophrenia and Bonferroni significant in DD/ID. The degree of association from each sequencing study is displayed as the color corresponding to −log₁₀ P values in that study. The two-sided case-control burden test P value is reported for schizophrenia, while one-sided P value from the *de novo* enrichment using the Poisson rate test is reported for DD/ID. Results are further stratified to tests of Class I (PTV and MPC > 3) and Class II (missense [MPC 2 – 3]) variants. C: Allelic series in *TRIO* between schizophrenia and DD/ID risk variants. The gene plot displays the protein-coding variants that contribute to the exome signal in *TRIO*. Variants discovered in schizophrenia cases are plotted above the gene, and missense *de novo* mutations from DD/ID probands are plotted below. Each variant is colored based on inferred consequence, and the protein domains of the gene are also labelled. The variant counts are displayed for each variant class. D: Allelic series in *GRIN2A.* See D for description.

**Figure 6.. The contributions of ultra-rare PTVs to schizophrenia risk.**
A: Genetic architecture of schizophrenia. Significant genetic associations for schizophrenia from the most recent GWAS, CNV, and sequencing studies are displayed. The in-sample odds ratio is plotted against the minor allele frequency in the general population. The color of each dot corresponds to the source of the association, and the size of the dot to the odds ratio. The shaded area represented the loess-smoothed lines of the upper and lower bounds of the point estimates. B: Case-control enrichment of ultra-rare protein-coding variants in genes intolerant of protein-truncating variants after excluding schizophrenia-associate genes (n = 22,444 cases and n = 39,837 controls). We perform the test with all constrained genes (pLI > 0.9) and after excluding all schizophrenia-associated genes with FDR < 5%. Two-sided P values from logistic regression displayed are from comparing the burden of variants of the labeled consequence in cases compared to controls. The dot represents the odds ratio, and the bars represent the 95% CIs of the point estimates.

See this image and copyright information in PMC

Comment in

Genetic origins of schizophrenia find common ground.
Iyegbe CO, O'Reilly PF. Iyegbe CO, et al. Nature. 2022 Apr;604(7906):433-435. doi: 10.1038/d41586-022-00773-5. Nature. 2022. PMID: 35411108 No abstract available.

Cited by

Neurodevelopmental disturbances in schizophrenia: evidence from genetic and environmental factors.
Schmitt A, Falkai P, Papiol S. Schmitt A, et al. J Neural Transm (Vienna). 2023 Mar;130(3):195-205. doi: 10.1007/s00702-022-02567-5. Epub 2022 Nov 12. J Neural Transm (Vienna). 2023. PMID: 36370183 Free PMC article. Review.
Clinical manifestations of schizophrenia in four patients with variants in voltage-gated calcium channel-encoding genes: a case series.
Lo T, Kushima I, Aleksic B, Yoshimi A, Someya T, Watanabe Y, Ozaki N. Lo T, et al. Psychiatry Clin Neurosci. 2023 Jan;77(1):57-59. doi: 10.1111/pcn.13494. Epub 2022 Nov 9. Psychiatry Clin Neurosci. 2023. PMID: 36271890 Free PMC article. No abstract available.
Enhancement of mediodorsal thalamus rescues aberrant belief dynamics in a mouse model with schizophrenia-associated mutation.
Zhou T, Ho YY, Lee RX, Fath AB, He K, Scott J, Bajwa N, Hartley ND, Wilde J, Gao X, Li C, Hong E, Nassar MR, Wimmer RD, Singh T, Halassa MM, Feng G. Zhou T, et al. bioRxiv [Preprint]. 2024 Feb 14:2024.01.08.574745. doi: 10.1101/2024.01.08.574745. bioRxiv. 2024. PMID: 38260581 Free PMC article. Preprint.
Implications of SNP-triggered miRNA dysregulation in Schizophrenia development.
Mohamed FA, Freude K. Mohamed FA, et al. Front Genet. 2024 Jan 26;15:1321232. doi: 10.3389/fgene.2024.1321232. eCollection 2024. Front Genet. 2024. PMID: 38343691 Free PMC article. Review.
Parkinson's disease and schizophrenia interactomes contain temporally distinct gene clusters underlying comorbid mechanisms and unique disease processes.
Karunakaran KB, Jain S, Brahmachari SK, Balakrishnan N, Ganapathiraju MK. Karunakaran KB, et al. Schizophrenia (Heidelb). 2024 Feb 27;10(1):26. doi: 10.1038/s41537-024-00439-3. Schizophrenia (Heidelb). 2024. PMID: 38413605 Free PMC article.

See all "Cited by" articles

References

1. Satterstrom FK et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell (2020) doi:10.1016/j.cell.2019.12.036. - DOI - PMC - PubMed
1. Kaplanis J et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature (2020) doi:10.1038/s41586-020-2832-5. - DOI - PMC - PubMed
1. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke S, Walters JTR & O’Donovan MC Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv (2020) doi:10.1101/2020.09.12.20192922. - DOI
1. McGrath J, Saha S, Chant D & Welham J Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. Epidemiol. Rev 30, 67–76 (2008). - PubMed
1. Hjorthøj C, Stürup AE, McGrath JJ & Nordentoft M Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. The Lancet Psychiatry 4, 295–301 (2017). - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Satterstrom FK et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell (2020) doi:10.1016/j.cell.2019.12.036. - DOI - PMC - PubMed

[2] Satterstrom FK et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell (2020) doi:10.1016/j.cell.2019.12.036. - DOI - PMC - PubMed

[3] Kaplanis J et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature (2020) doi:10.1038/s41586-020-2832-5. - DOI - PMC - PubMed

[4] Kaplanis J et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature (2020) doi:10.1038/s41586-020-2832-5. - DOI - PMC - PubMed

[5] Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke S, Walters JTR & O’Donovan MC Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv (2020) doi:10.1101/2020.09.12.20192922. - DOI

[6] Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke S, Walters JTR & O’Donovan MC Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv (2020) doi:10.1101/2020.09.12.20192922. - DOI

[7] McGrath J, Saha S, Chant D & Welham J Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. Epidemiol. Rev 30, 67–76 (2008). - PubMed

[8] McGrath J, Saha S, Chant D & Welham J Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. Epidemiol. Rev 30, 67–76 (2008). - PubMed

[9] Hjorthøj C, Stürup AE, McGrath JJ & Nordentoft M Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. The Lancet Psychiatry 4, 295–301 (2017). - PubMed

[10] Hjorthøj C, Stürup AE, McGrath JJ & Nordentoft M Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. The Lancet Psychiatry 4, 295–301 (2017). - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Rare coding variants in ten genes confer substantial risk for schizophrenia

Affiliations

Rare coding variants in ten genes confer substantial risk for schizophrenia

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous